For prescribing information and adverse event reporting, click here

This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

Resources

Renal Cell Carcinoma

Cabozantinib Ipsen therapeutic indications

Cabozantinib Ipsen® is indicated as monotherapy for advanced renal cell carcinoma:

  • as first-line treatment of adult patients with intermediate or poor risk,
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Cabozantinib Ipsen, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

Real World Experience

HCP experience of using cabozantinib + nivolumab to treat patients with aRCC
HCP experience of using cabozantinib + nivolumab to treat patients with aRCC
Video 03:18

Hear from Prof. Laurence Albiges and Prof. James Larkin sharing their experience of using Cabo+Nivo to treat patients with aRCC.

CBZ-UK-000344 | November 2024
Supporting Patients with aRCC during treatment with cabozantinib + nivolumab
Supporting Patients with aRCC during treatment with cabozantinib + nivolumab
Video 04:28

Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.

CBZ-UK-000345 | November 2024
Importance of cabozantinib + nivolumab for the treatment of aRCC
Importance of cabozantinib + nivolumab for the treatment of aRCC
Video 05:40

Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.

CBZ-UK-000341 | November 2024

Adverse Event Management

IO/TKI Toxicity – How to work out which toxicities are coming from which drug
IO/TKI Toxicity – How to work out which toxicities are coming from which drug
Video 17:10

Toxicity Management with combination treatment – How to work out which toxicities are coming from which drug.

CBZ-UK-000346 | November 2024
Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma
Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma
PDF / PowerPoint Deck 17 pages

A guide for healthcare professionals

CBZ-UK-000342 | November 2024

Product Resources

Checkmate 9ER Trial: Data Summary
Checkmate 9ER Trial: Data Summary

Early efficacy with sustained long-term overall survival vs sunitinib: At a median follow-up of 67.6 months (60.2 months minimum), CheckMate 9ER data for Cabozantinib + nivolumab demonstrate an 11-month longer mOS vs sunitinib.

CBZ-UK-000470 | March 2025

eLearning

Background to renal cell carcinoma
Background to renal cell carcinoma
PDF / PowerPoint Deck 19 pages

Pathology of kidney cancer and renal cell carcinoma (RCC). Epidemiology of kidney cancer and RCC. Staging and prognosis of RCC. Treatment of RCC.

CBZ-UK-000340 | November 2024

Contact your Ipsen representative

Send request
Resources

To access relevant information about Renal Cell Carcinoma, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 
01753 627777.

I am a patient

This section provides information to support patients that have been prescribed Cabozantinib Ipsen.

I am a patient

I am a member of the general public

This section is for members
of the general public.

I am a member of the general public

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.